Unum Therapeutics Inc. (UMRX) Tops Q4 EPS by 6c, Revenues Beat

Unum Therapeutics Inc. (NASDAQ: UMRX) reported Q4 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $2.64 million.

“2018 was an important year for Unum as we brought the company public and continued to innovate in cell therapy with the advancement of our ACTR platform and the development of our new BOXR platform,” said Chuck Wilson, President and CEO of Unum. “We have demonstrated proof of concept with the ACTR approach and see a clear path to further evaluating differentiated, potentially best-in-class product candidates designed to address continued patient needs. We are building out our solid tumor pipeline and have initiated our first solid tumor clinical trial, ATTCK-34-01, and selected BOXR1030 as our first product candidate from the BOXR platform. In 2019, we look forward to reporting data from all of our ongoing trials that will help determine next steps for our efforts in non-Hodgkin lymphoma, multiple myeloma, and solid tumors.”

For earnings history and earnings-related data on Unum Therapeutics Inc. (UMRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M